

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Dennis France, et al.

APPLICATION NO: 10/035,301

FILED: October 25, 2001

FOR: Use of 2, 4diamino-3-hydroxycarbocyclic acid derivatives as
proteasome inhibitors

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement of October 1, 2007, Applicants elect, *with traverse*, the invention of Group I, claims 8-15, drawn to compounds of formula I, and a pharmaceutical composition thereof, classified in class 514, subclass 2. Applicants provisionally elect the following species to assist the Examiner in searching: {1-[1-Benzyl-2-hydroxy-3-[1-(2-hydroxy-4-methoxy-benzylcarbonyl)-2-methyl-propylcarbonyl]-3-(4-methoxy-benzylamino)-propylcarbonyl]-2,2-dimethyl-propyl}-carbamic acid 3-methylbenzyl ester.

A Petition for five months' extension of time is submitted herewith, which makes this response timely. However, if it is deemed that additional fees are required, the Commissioner is authorized to charge Deposit Account No. 50-4409 in the name of Novartis for any fees due.

Applicants reserve the right to prosecute the subject matter of any non-elected claim groups in one or more divisional applications.

An early and favorable action on the merits is respectfully requested.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
400 Technology Square
Cambridge, MA 02139

(617) 871-3343


Paul J. Paglierani
Attorney for Applicant
Reg. No. 52,498

Date: April 1, 2008